Coherus Oncology, Inc. Operating Expenses
Coherus Oncology, Inc. (CHRS) reported Operating Expenses of $79.83 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2020-11-05
- Coherus Oncology, Inc. operating expenses for the quarter ending 2020-09-30 was $79.83M, a 33.41% increase year-over-year.
- Coherus Oncology, Inc. operating expenses for the quarter ending 2020-06-30 was $70.36M, a 25.78% increase year-over-year.
- Coherus Oncology, Inc. operating expenses for the quarter ending 2020-03-31 was $75.31M, a 40.25% increase year-over-year.
- Coherus Oncology, Inc. operating expenses for the quarter ending 2019-12-31 was $78.82M, a 30.28% increase year-over-year.
- Coherus Oncology, Inc. operating expenses for fiscal 2019 was $248.30M, a 21.47% increase from fiscal 2018.
- Coherus Oncology, Inc. operating expenses for fiscal 2018 was $204.42M, a 12.53% decline from fiscal 2017.
- Coherus Oncology, Inc. operating expenses for fiscal 2017 was $233.69M, a 23.64% decline from fiscal 2016.
- Coherus Oncology, Inc. operating expenses for fiscal 2016 was $306.04M, a 22.85% increase from fiscal 2015.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2020-09-30 | $79.83M 10-Q · filed 2020-11-05 | $150.20M derived: sum of 2 quarters · filed 2020-11-05 | $225.51M 10-Q · filed 2020-11-05 | $304.33M derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-06-30 | $70.36M 10-Q · filed 2020-08-06 | $145.68M 10-Q · filed 2020-08-06 | $224.50M derived: sum of 3 quarters · filed 2020-08-06 | $284.34M derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-03-31 | $75.31M 10-Q · filed 2020-05-07 | $154.13M derived: sum of 2 quarters · filed 2020-05-07 | $213.98M derived: sum of 3 quarters · filed 2020-11-05 | $269.92M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-12-31 | $78.82M 10-K · filed 2020-02-27 | $138.67M derived: sum of 2 quarters · filed 2020-11-05 | $194.61M derived: sum of 3 quarters · filed 2020-11-05 | $248.30M 10-K · filed 2020-02-27 |
| 2019-09-30 | $59.84M 10-Q · filed 2020-11-05 | $115.78M derived: sum of 2 quarters · filed 2020-11-05 | $169.48M 10-Q · filed 2020-11-05 | $229.98M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $55.94M 10-Q · filed 2020-08-06 | $109.64M 10-Q · filed 2020-08-06 | $170.14M derived: sum of 3 quarters · filed 2020-08-06 | $227.11M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $53.70M 10-Q · filed 2020-05-07 | $114.20M derived: sum of 2 quarters · filed 2020-05-07 | $171.17M derived: sum of 3 quarters · filed 2020-05-07 | $216.08M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $60.50M 10-K · filed 2020-02-27 | $117.47M derived: sum of 2 quarters · filed 2020-02-27 | $162.38M derived: sum of 3 quarters · filed 2020-02-27 | $204.42M 10-K · filed 2020-02-27 |
| 2018-09-30 | $56.97M 10-K · filed 2020-02-27 | $101.88M derived: sum of 2 quarters · filed 2020-02-27 | $143.91M 10-Q · filed 2019-11-08 | $190.38M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $44.91M 10-K · filed 2020-02-27 | $86.94M 10-Q · filed 2019-08-05 | $133.41M derived: sum of 3 quarters · filed 2020-02-27 | $190.02M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $42.03M 10-K · filed 2020-02-27 | $88.50M derived: sum of 2 quarters · filed 2020-02-27 | $145.11M derived: sum of 3 quarters · filed 2020-02-27 | $203.15M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $46.47M 10-K · filed 2019-02-28 | $103.08M derived: sum of 2 quarters · filed 2019-02-28 | $161.11M derived: sum of 3 quarters · filed 2019-02-28 | $233.69M 10-K · filed 2020-02-27 |
| 2017-09-30 | $56.62M 10-K · filed 2019-02-28 | $114.65M derived: sum of 2 quarters · filed 2019-02-28 | $187.23M 10-Q · filed 2018-11-08 | $261.53M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $58.03M 10-K · filed 2019-02-28 | $130.61M 10-Q · filed 2018-08-08 | $204.91M derived: sum of 3 quarters · filed 2019-02-28 | $283.13M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $72.58M 10-K · filed 2019-02-28 | $146.88M derived: sum of 2 quarters · filed 2019-02-28 | $225.10M derived: sum of 3 quarters · filed 2019-02-28 | $301.90M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $74.30M 10-K · filed 2018-03-08 | $152.52M derived: sum of 2 quarters · filed 2018-03-08 | $229.33M derived: sum of 3 quarters · filed 2018-03-08 | $306.04M 10-K · filed 2019-02-28 |
| 2016-09-30 | $78.22M 10-K · filed 2018-03-08 | $155.02M derived: sum of 2 quarters · filed 2018-03-08 | $231.73M 10-Q · filed 2017-11-06 | $294.14M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $76.80M 10-K · filed 2018-03-08 | $153.51M 10-Q · filed 2017-08-07 | $215.92M derived: sum of 3 quarters · filed 2018-03-08 | $294.30M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $76.71M 10-K · filed 2018-03-08 | $139.12M derived: sum of 2 quarters · filed 2018-03-08 | $217.50M derived: sum of 3 quarters · filed 2018-03-08 | $283.26M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $62.41M 10-K · filed 2017-03-14 | $140.79M derived: sum of 2 quarters · filed 2017-03-14 | $206.55M derived: sum of 3 quarters · filed 2017-03-14 | $249.11M 10-K · filed 2018-03-08 |
| 2015-09-30 | $78.38M 10-K · filed 2017-03-14 | $144.15M derived: sum of 2 quarters · filed 2017-03-14 | $186.70M 10-Q · filed 2016-11-09 | $219.76M derived: sum of 4 quarters · filed 2017-03-14 |
| 2015-06-30 | $65.76M 10-K · filed 2017-03-14 | $108.32M 10-Q · filed 2016-08-09 | $141.37M derived: sum of 3 quarters · filed 2017-03-14 | $163.85M derived: sum of 4 quarters · filed 2017-03-14 |
| 2015-03-31 | $42.56M 10-K · filed 2017-03-14 | $75.61M derived: sum of 2 quarters · filed 2017-03-14 | $98.09M derived: sum of 3 quarters · filed 2017-03-14 | $120.99M derived: sum of 4 quarters · filed 2017-03-14 |
| 2014-12-31 | $33.05M 10-K · filed 2016-02-29 | $55.53M derived: sum of 2 quarters · filed 2016-02-29 | $78.43M derived: sum of 3 quarters · filed 2016-02-29 | $95.79M 10-K · filed 2017-03-14 |
| 2014-09-30 | $22.48M 10-K · filed 2016-02-29 | $45.38M derived: sum of 2 quarters · filed 2016-02-29 | $62.73M 10-Q · filed 2015-11-10 | $74.45M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $22.90M 10-K · filed 2016-02-29 | $40.26M 10-Q · filed 2015-08-10 | $51.98M derived: sum of 3 quarters · filed 2016-02-29 | $59.27M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $17.36M 10-K · filed 2016-02-29 | $29.08M derived: sum of 2 quarters · filed 2016-02-29 | $36.37M derived: sum of 3 quarters · filed 2016-02-29 | $46.16M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $11.72M 10-K · filed 2015-03-23 | $19.01M derived: sum of 2 quarters · filed 2015-03-23 | $28.80M derived: sum of 3 quarters · filed 2015-03-23 | $38.74M 10-K · filed 2016-02-29 |
| 2013-09-30 | $7.29M 10-K · filed 2015-03-23 | $17.08M derived: sum of 2 quarters · filed 2015-03-23 | $27.02M 10-Q · filed 2014-12-15 | |
| 2013-06-30 | $9.79M 10-K · filed 2015-03-23 | $19.74M derived: sum of 2 quarters · filed 2015-03-23 | ||
| 2013-03-31 | $9.95M 10-K · filed 2015-03-23 | |||
| 2012-12-31 | $40.42M 10-K · filed 2015-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |